Asghar Rahmani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Asghar Rahmani has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Ali Saberi
Mashhad University of Medical Science, School of Medicine, Mashhad, Iran
1 shared publication- Atefeh Rahimi
Department of Physiology, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication - Ava Bolandparvaz
Department of Antibody Development, Aviva Systems Biology, San Diego, USA
1 shared publication Fardin Naqiloo
Department of Laboratory Sciences, Faculty of Medical Sciences, Islamic Azad University, Marand Branch, Marand, Iran
1 shared publicationFatemeh Sadeghipour
Mashhad University of Medical Science, Vascular Surgery Research Center, Mashhad, Iran
1 shared publicationGholamreza Kazemzadeh
Mashhad University of Medical Science, School of Medicine, Mashhad, Iran
1 shared publication
Latest Publications
- Open Access
- 21 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Bifidobacterium adolescentis attenuates cardiac remodeling in HFD/STZ-induced obesity-associated diabetic cardiomyopathy
Obesity-associated diabetic cardiomyopathy is characterized by cardiac structural remodeling and modification of gene expression. Increasing evidence has led to the conclusion that gut microbiota, particularly probiotics, may modulate cardiac health through systemic and molecular pathways. The aim of the current study was to explore the cardioprotective effects of Bifidobacterium adolescentis on cardiac structure and gene expression in a rat model of high-fat diet (HFD) and low-dose streptozotocin (STZ)-induced obesity-associated diabetic cardiomyopathy. Male Wistar rats were divided into the following four groups: control, HFD, HFD- B. adolescentis (8 weeks), and HFD-B. adolescentis (16 weeks). Stereological studies were conducted to quantify left ventricular and myocardial volume. Real-time PCR was used to quantify the levels of genes associated with cardiac stress, fibrosis, inflammation, and contractility, like ANP, BNP, TGF-β, GATA4, Myc, Nfkb1, NPR1, Kcnq1, MEF2D, and SERCA2a. HFD/STZ treatment significantly increased heart weight (+ 68%) and left ventricular volume (+ 63%), elevated myocardial volume (+ 42%), and reduced vascular volume. Hypertrophic and inflammatory genes (ANP, BNP, TGF-β, GATA4, Myc, Nfkb1) were markedly upregulated, while contractility-related genes (MEF2D, SERCA2a, NPR1, KCNQ1) were downregulated. B. adolescentis supplementation for 8–16 weeks reversed these alterations, normalizing structural indices and restoring gene expression toward control levels. Bifidobacterium adolescentis attenuated obesity- and hyperglycemia-associated cardiac remodeling by improving structural and molecular parameters. These findings identify B. adolescentis as a potential probiotic candidate for preventing obesity-associated diabetic cardiomyopathy.
- 21 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessBifidobacterium adolescentis attenuates cardiac remodeling in HFD/STZ-induced obesity-associated diabetic cardiomyopathy
Obesity-associated diabetic cardiomyopathy is characterized by cardiac structural remodeling and modification of gene expression. Increasing evidence has led to the conclusion that gut microbiota, particularly probiotics, may modulate cardiac health through systemic and molecular pathways. The aim of the current study was to explore the cardioprotective effects of Bifidobacterium adolescentis on cardiac structure and gene expression in a rat model of high-fat diet (HFD) and low-dose streptozotocin (STZ)-induced obesity-associated diabetic cardiomyopathy. Male Wistar rats were divided into the following four groups: control, HFD, HFD- B. adolescentis (8 weeks), and HFD-B. adolescentis (16 weeks). Stereological studies were conducted to quantify left ventricular and myocardial volume. Real-time PCR was used to quantify the levels of genes associated with cardiac stress, fibrosis, inflammation, and contractility, like ANP, BNP, TGF-β, GATA4, Myc, Nfkb1, NPR1, Kcnq1, MEF2D, and SERCA2a. HFD/STZ treatment significantly increased heart weight (+ 68%) and left ventricular volume (+ 63%), elevated myocardial volume (+ 42%), and reduced vascular volume. Hypertrophic and inflammatory genes (ANP, BNP, TGF-β, GATA4, Myc, Nfkb1) were markedly upregulated, while contractility-related genes (MEF2D, SERCA2a, NPR1, KCNQ1) were downregulated. B. adolescentis supplementation for 8–16 weeks reversed these alterations, normalizing structural indices and restoring gene expression toward control levels. Bifidobacterium adolescentis attenuated obesity- and hyperglycemia-associated cardiac remodeling by improving structural and molecular parameters. These findings identify B. adolescentis as a potential probiotic candidate for preventing obesity-associated diabetic cardiomyopathy.
- Open Access
- 1 June 2019
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 41 (2) , 185-192
Effect of local papaverine on arteriovenous fistula maturation in patients with end-stage renal disease
Background: Arteriovenous fistula (AVF) maturation is one of the main concerns in patients with end-stage renal disease (ESRD) and finding a strategy for increasing success rate and accelerating fistula maturation is valuable. The aim of this study was to evaluate the effects of papaverine injection on AVF maturation and success rate. Method: This study was a randomized clinical trial that involved 110 patients with ESRD that were referred for AVF construction. Patients were allocated in papaverine group and control group with block randomization according to age and sex. In the case group, papaverine (0.1 or 0.2 cc) was injected locally within the subadventitia of artery and vein after proximal and distal control during AVF construction and in the control group, AVF construction was done routinely without papaverine injection. Results: Maturation time in case and control groups was 37.94 ± 11.49 and 44.23 ± 9.57 days, respectively (p=0.004). Hematoma was not seen in the case group but occurred in one patient in the control group. One patient of the case group developed venous hypertension. Four functional fistulas, 1 (1.8%) in the case group and 3 (5.5%) in the control group, failed to mature (p=0.618). Maturation rate did not differ between the two groups statistically (p=0.101). Conclusion: Local papaverine injection increased vessel diameter and blood flow, increasing shearing stress in both arterial and venous segment of recently created AVF. In this way, papaverine probably can decrease AVF maturation time without an increase in complications.
- 1 June 2019
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 41 (2) , 185-192
Open AccessEffect of local papaverine on arteriovenous fistula maturation in patients with end-stage renal disease
Background: Arteriovenous fistula (AVF) maturation is one of the main concerns in patients with end-stage renal disease (ESRD) and finding a strategy for increasing success rate and accelerating fistula maturation is valuable. The aim of this study was to evaluate the effects of papaverine injection on AVF maturation and success rate. Method: This study was a randomized clinical trial that involved 110 patients with ESRD that were referred for AVF construction. Patients were allocated in papaverine group and control group with block randomization according to age and sex. In the case group, papaverine (0.1 or 0.2 cc) was injected locally within the subadventitia of artery and vein after proximal and distal control during AVF construction and in the control group, AVF construction was done routinely without papaverine injection. Results: Maturation time in case and control groups was 37.94 ± 11.49 and 44.23 ± 9.57 days, respectively (p=0.004). Hematoma was not seen in the case group but occurred in one patient in the control group. One patient of the case group developed venous hypertension. Four functional fistulas, 1 (1.8%) in the case group and 3 (5.5%) in the control group, failed to mature (p=0.618). Maturation rate did not differ between the two groups statistically (p=0.101). Conclusion: Local papaverine injection increased vessel diameter and blood flow, increasing shearing stress in both arterial and venous segment of recently created AVF. In this way, papaverine probably can decrease AVF maturation time without an increase in complications.